Abivax Leads Biotechnology Stocks in Year-to-Date Performance
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 22 2025
0mins
Source: SeekingAlpha
Healthcare Sector Performance: The S&P healthcare index (XLV) experienced a YTD increase of 12.2% by mid-December 2025, ranking as the sixth-highest performing sector among the S&P 500 indexes.
Top Biotechnology Stocks: ABIVAX Société Anonyme (ABVX) leads the biotechnology sector with an impressive YTD performance of +1,470.22%, followed by Cidara Therapeutics (CDTX) and Celcuity (CELC) with gains of +721.43% and +672.80%, respectively.
Notable Performers: GRAIL (GRAL) ranks fourth with a YTD performance of +410.31% and holds the highest Quant Rating of Strong Buy 4.98, while Cogent Biosciences (COGT) rounds out the top five with +407.05%.
Healthcare ETFs: Various healthcare ETFs, including XLV, VHT, and IHI, are highlighted, along with predictions for sector outperformers and laggards in 2026.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ABVX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ABVX
Wall Street analysts forecast ABVX stock price to rise
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 144.650
Low
131.00
Averages
150.71
High
175.00
Current: 144.650
Low
131.00
Averages
150.71
High
175.00
About ABVX
Abivax SA is a clinical stage biopharmaceutical company focusing on the discovery, development and commercialization of anti-viral compounds and therapeutic vaccines against severe and life threatening infectious diseases. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The Company's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Abivax Completes $920M Public Offering with Full Underwriter Option Exercise
- Offering Expansion: Abivax's U.S. public offering saw underwriters fully exercise their option for an additional 960K American Depositary Shares (ADSs), bringing the total offering to 7.36 million ADSs, with expected gross proceeds of approximately $920 million and net proceeds of $874.1 million, indicating strong market support for its financing needs.
- Pricing Strategy: The additional ADSs were priced at $125 each, equivalent to €109.71 per ordinary share based on the European Central Bank's June 30 exchange rate, matching the volume-weighted average price of Abivax's ordinary shares on Euronext Paris over the preceding three trading days, reflecting investor confidence in the company's valuation.
- Clear Use of Proceeds: Abivax plans to allocate the net proceeds towards clinical research and development expenses primarily related to ulcerative colitis and Crohn’s disease, as well as potential commercialization of its lead drug candidate, obefazimod, in the U.S., demonstrating the company's commitment to advancing its drug pipeline.
- Positive Market Reaction: Following the public offering announcement, ABVX shares rose 3.7% in premarket trading, indicating increased investor confidence in the company's future prospects, which may further enhance its market performance.
See More
Abivax Increases Offering to 7.36 Million Shares, Raising $874.1 Million
- Offering Expansion: Abivax has increased its offering size from an initial 6.4 million shares to 7.36 million shares, expecting to raise approximately $920 million in gross proceeds at $125 per share, with net proceeds projected at $874.1 million after underwriting fees, significantly bolstering the company's financial resources for future growth.
- Clear Use of Proceeds: The funds raised will support the potential U.S. commercialization of its lead drug candidate, Obefazimod, fund clinical research and development programs primarily focused on ulcerative colitis and Crohn's disease, and cover general corporate purposes, demonstrating the company's commitment to drug development.
- Positive Clinical Trial Results: Recent Phase 3 trial results for Obefazimod revealed that 37.2% of patients who did not respond to initial therapy achieved clinical remission, while increasing the dose helped 45.5% of relapsed patients regain remission, further validating the drug's efficacy and safety profile.
- Optimistic Market Sentiment: Retail sentiment surrounding ABVX on Stocktwits remains in the 'bullish' territory, with increased chatter about a potential buyout, as some users anticipate the company could be acquired by the end of the year, reflecting investor confidence in the company's future prospects.
See More
Abivax Fully Exercises Underwriters' Option for Additional ADS Purchase
- Expanded Financing: Abivax has fully exercised the underwriters' option to purchase an additional 960,000 American Depositary Shares (ADSs), bringing the total gross proceeds of the offering to approximately $920 million (€807 million), significantly enhancing the company's financial strength for future growth.
- Clear Use of Proceeds: The estimated net proceeds from this offering are approximately $874.1 million (€767.1 million), which will primarily fund the development of the lead drug candidate obefazimod and clinical research related to ulcerative colitis and Crohn's disease, reflecting the company's commitment to R&D.
- Positive Market Response: The offering price for each additional ADS is set at $125, representing a 2.39% premium over the volume-weighted average price from the last three trading days, indicating strong market confidence in Abivax's growth potential, which may drive stock price appreciation.
- Strategic Planning: Abivax aims to close this offering on July 6, 2026, further solidifying its market position in the biotechnology sector and laying the groundwork for drug commercialization in the U.S., showcasing the company's proactive approach to future market opportunities.
See More
Abivax Raises $800 Million Through ADS Offering
- Increased Offering Size: Abivax announced a public offering of 6.4 million American Depositary Shares (ADSs) at $125 each, raising the total offering size from $600 million to $800 million, reflecting strong market confidence in its drug candidate.
- Clear Use of Proceeds: The net proceeds from the offering will be allocated towards the commercialization of the lead drug candidate obefazimod in the U.S. and clinical research, effectively supporting the company's operational funding needs until Q2 2029.
- Extended Cash Runway: As of March 31, Abivax reported approximately €491.6 million in cash and cash equivalents, and with the new funding, the company expects to extend its cash runway into Q2 2029, enhancing its survival prospects in the market.
- Optimistic Market Sentiment: Despite the offering leading to an 8% dilution of share capital, retail sentiment on Stocktwits remains bullish, indicating strong confidence in Abivax's future growth potential.
See More
ABIVAX Prices Public Offering of 6.4 Million ADSs
- Offering Size: ABIVAX announced the pricing of 6.4 million American Depositary Shares (ADS) at $125 each, expected to raise approximately $800 million for the commercialization of its lead drug candidate, obefazimod, and clinical research expenses.
- Underwriter Option: The underwriters have an option to purchase up to an additional 960,000 ADSs, enhancing the flexibility of the financing and ensuring the company has greater security for future funding needs.
- Positive Market Reaction: In pre-market trading, ABIVAX's stock rose 2.80% to $136.99 on Nasdaq, reflecting investor confidence in the company's future and recognition of its drug development potential.
- Clear Use of Funds: The proceeds will primarily fund clinical research and development related to ulcerative colitis and Crohn's disease, indicating the company's strategic focus in the gastrointestinal disease sector and aiming to accelerate its product commercialization efforts.
See More
Abivax Prices Oversubscribed $800M Public Offering
- Upsized Offering: Abivax has increased its public offering from the initially planned $600 million to $800 million, pricing each American Depositary Share (ADS) at $125, reflecting a 2.39% premium over the three-day VWAP, indicating strong market demand and expected gross proceeds of approximately $800 million to support future commercialization and clinical development.
- Clear Use of Proceeds: The funds raised will be allocated to support the commercialization of its lead drug candidate, obefazimod, and clinical research related to ulcerative colitis and Crohn's disease, extending the company's cash runway into Q2 2029, ensuring continued operations in the competitive biopharmaceutical market.
- Underwriters' Option: The company has granted underwriters an option to purchase up to 960,000 additional ADSs before July 6, 2026, which, if fully exercised, could raise total proceeds to approximately $920 million, further strengthening the company's financial position for R&D and market expansion.
- Dilution Impact: The issuance of 6.4 million ADSs will result in an approximate 8% dilution of the company's share capital, increasing to 9.2% if the underwriters' option is fully exercised, which may affect existing shareholders' stakes and warrants investor attention.
See More
Abivax Completes $920M Public Offering with Full Underwriter Option Exercise
- Offering Expansion: Abivax's U.S. public offering saw underwriters fully exercise their option for an additional 960K American Depositary Shares (ADSs), bringing the total offering to 7.36 million ADSs, with expected gross proceeds of approximately $920 million and net proceeds of $874.1 million, indicating strong market support for its financing needs.
- Pricing Strategy: The additional ADSs were priced at $125 each, equivalent to €109.71 per ordinary share based on the European Central Bank's June 30 exchange rate, matching the volume-weighted average price of Abivax's ordinary shares on Euronext Paris over the preceding three trading days, reflecting investor confidence in the company's valuation.
- Clear Use of Proceeds: Abivax plans to allocate the net proceeds towards clinical research and development expenses primarily related to ulcerative colitis and Crohn’s disease, as well as potential commercialization of its lead drug candidate, obefazimod, in the U.S., demonstrating the company's commitment to advancing its drug pipeline.
- Positive Market Reaction: Following the public offering announcement, ABVX shares rose 3.7% in premarket trading, indicating increased investor confidence in the company's future prospects, which may further enhance its market performance.
See More
Abivax Increases Offering to 7.36 Million Shares, Raising $874.1 Million
- Offering Expansion: Abivax has increased its offering size from an initial 6.4 million shares to 7.36 million shares, expecting to raise approximately $920 million in gross proceeds at $125 per share, with net proceeds projected at $874.1 million after underwriting fees, significantly bolstering the company's financial resources for future growth.
- Clear Use of Proceeds: The funds raised will support the potential U.S. commercialization of its lead drug candidate, Obefazimod, fund clinical research and development programs primarily focused on ulcerative colitis and Crohn's disease, and cover general corporate purposes, demonstrating the company's commitment to drug development.
- Positive Clinical Trial Results: Recent Phase 3 trial results for Obefazimod revealed that 37.2% of patients who did not respond to initial therapy achieved clinical remission, while increasing the dose helped 45.5% of relapsed patients regain remission, further validating the drug's efficacy and safety profile.
- Optimistic Market Sentiment: Retail sentiment surrounding ABVX on Stocktwits remains in the 'bullish' territory, with increased chatter about a potential buyout, as some users anticipate the company could be acquired by the end of the year, reflecting investor confidence in the company's future prospects.
See More
Abivax Fully Exercises Underwriters' Option for Additional ADS Purchase
- Expanded Financing: Abivax has fully exercised the underwriters' option to purchase an additional 960,000 American Depositary Shares (ADSs), bringing the total gross proceeds of the offering to approximately $920 million (€807 million), significantly enhancing the company's financial strength for future growth.
- Clear Use of Proceeds: The estimated net proceeds from this offering are approximately $874.1 million (€767.1 million), which will primarily fund the development of the lead drug candidate obefazimod and clinical research related to ulcerative colitis and Crohn's disease, reflecting the company's commitment to R&D.
- Positive Market Response: The offering price for each additional ADS is set at $125, representing a 2.39% premium over the volume-weighted average price from the last three trading days, indicating strong market confidence in Abivax's growth potential, which may drive stock price appreciation.
- Strategic Planning: Abivax aims to close this offering on July 6, 2026, further solidifying its market position in the biotechnology sector and laying the groundwork for drug commercialization in the U.S., showcasing the company's proactive approach to future market opportunities.
See More
Abivax Raises $800 Million Through ADS Offering
- Increased Offering Size: Abivax announced a public offering of 6.4 million American Depositary Shares (ADSs) at $125 each, raising the total offering size from $600 million to $800 million, reflecting strong market confidence in its drug candidate.
- Clear Use of Proceeds: The net proceeds from the offering will be allocated towards the commercialization of the lead drug candidate obefazimod in the U.S. and clinical research, effectively supporting the company's operational funding needs until Q2 2029.
- Extended Cash Runway: As of March 31, Abivax reported approximately €491.6 million in cash and cash equivalents, and with the new funding, the company expects to extend its cash runway into Q2 2029, enhancing its survival prospects in the market.
- Optimistic Market Sentiment: Despite the offering leading to an 8% dilution of share capital, retail sentiment on Stocktwits remains bullish, indicating strong confidence in Abivax's future growth potential.
See More
ABIVAX Prices Public Offering of 6.4 Million ADSs
- Offering Size: ABIVAX announced the pricing of 6.4 million American Depositary Shares (ADS) at $125 each, expected to raise approximately $800 million for the commercialization of its lead drug candidate, obefazimod, and clinical research expenses.
- Underwriter Option: The underwriters have an option to purchase up to an additional 960,000 ADSs, enhancing the flexibility of the financing and ensuring the company has greater security for future funding needs.
- Positive Market Reaction: In pre-market trading, ABIVAX's stock rose 2.80% to $136.99 on Nasdaq, reflecting investor confidence in the company's future and recognition of its drug development potential.
- Clear Use of Funds: The proceeds will primarily fund clinical research and development related to ulcerative colitis and Crohn's disease, indicating the company's strategic focus in the gastrointestinal disease sector and aiming to accelerate its product commercialization efforts.
See More
Abivax Prices Oversubscribed $800M Public Offering
- Upsized Offering: Abivax has increased its public offering from the initially planned $600 million to $800 million, pricing each American Depositary Share (ADS) at $125, reflecting a 2.39% premium over the three-day VWAP, indicating strong market demand and expected gross proceeds of approximately $800 million to support future commercialization and clinical development.
- Clear Use of Proceeds: The funds raised will be allocated to support the commercialization of its lead drug candidate, obefazimod, and clinical research related to ulcerative colitis and Crohn's disease, extending the company's cash runway into Q2 2029, ensuring continued operations in the competitive biopharmaceutical market.
- Underwriters' Option: The company has granted underwriters an option to purchase up to 960,000 additional ADSs before July 6, 2026, which, if fully exercised, could raise total proceeds to approximately $920 million, further strengthening the company's financial position for R&D and market expansion.
- Dilution Impact: The issuance of 6.4 million ADSs will result in an approximate 8% dilution of the company's share capital, increasing to 9.2% if the underwriters' option is fully exercised, which may affect existing shareholders' stakes and warrants investor attention.
See More
